These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 26034641)
1. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma. Back M; Gzell CE; Kastelan M; Guo L; Wheeler HR Neurooncol Pract; 2015 Mar; 2(1):48-53. PubMed ID: 26034641 [TBL] [Abstract][Full Text] [Related]
2. The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma. Chan J; Jayamanne D; Wheeler H; Khasraw M; Wong M; Kastelan M; Guo L; Back M Clin Transl Radiat Oncol; 2020 May; 22():33-39. PubMed ID: 32195378 [TBL] [Abstract][Full Text] [Related]
3. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse. Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747 [TBL] [Abstract][Full Text] [Related]
4. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma. Cuncannon M; Wong M; Jayamanne D; Guo L; Cove N; Wheeler H; Back M BMC Cancer; 2019 May; 19(1):445. PubMed ID: 31088401 [TBL] [Abstract][Full Text] [Related]
5. Re-irradiation treatment regimens for patients with recurrent glioma - Evaluation of the optimal dose and best concurrent therapy. Fleischmann DF; Gajdi L; Corradini S; Schönecker S; Marschner S; Bodensohn R; Hofmaier J; Garny S; Forbrig R; Thon N; Belka C; Niyazi M Radiother Oncol; 2024 Oct; 199():110437. PubMed ID: 39013502 [TBL] [Abstract][Full Text] [Related]
6. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review. Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887 [TBL] [Abstract][Full Text] [Related]
11. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828 [TBL] [Abstract][Full Text] [Related]
12. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study. Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269 [TBL] [Abstract][Full Text] [Related]
13. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model. Müller K; Henke G; Pietschmann S; van Gool S; De Vleeschouwer S; von Bueren AO; Compter I; Friedrich C; Matuschek C; Klautke G; Kortmann RD; Hundsberger T; Baumert BG J Neurooncol; 2015 Sep; 124(2):325-32. PubMed ID: 26070556 [TBL] [Abstract][Full Text] [Related]
14. How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment. Massimino M; Vennarini S; Barretta F; Colombo F; Antonelli M; Pollo B; Pignoli E; Pecori E; Alessandro O; Schiavello E; Boschetti L; Podda M; Puma N; Gattuso G; Sironi G; Barzanò E; Nigro O; Bergamaschi L; Chiaravalli S; Luksch R; Meazza C; Spreafico F; Terenziani M; Casanova M; Ferrari A; Chisari M; Pellegrini C; Clerici CA; Modena P; Biassoni V J Neurooncol; 2022 Sep; 159(2):437-445. PubMed ID: 35809148 [TBL] [Abstract][Full Text] [Related]
15. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784 [TBL] [Abstract][Full Text] [Related]
16. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052 [TBL] [Abstract][Full Text] [Related]
17. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors. You WC; Lee HD; Pan HC; Chen HC Sci Rep; 2023 Jun; 13(1):9442. PubMed ID: 37296207 [TBL] [Abstract][Full Text] [Related]
18. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467 [TBL] [Abstract][Full Text] [Related]
19. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists. Furlan C; Arcangeli S; Avanzo M; Mirri MA; Munoz F; Giudici S; Perrone A; Amelio D; Tomio L; Draghini L; Deli AM; Pavanato G; Giuliano FM; Pontoriero A; Ciammella P; Navarria P; Iannalfi A; Buglione M; Guida C; Cammelli S; Iorio V; Cardinali M; Genovesi D; Barsacchi L; Balducci M; Bagnoli R; Berti F; Montesi G; Pasqualetti F; Bonome P; Santoni R; Doino D; Schirru P; Pinzi V; Borzillo V; Ferrarese F; Ferro M; Cicco L; Krengli M; Scoccianti S; Donato V Tumori; 2018 Dec; 104(6):466-470. PubMed ID: 28315510 [TBL] [Abstract][Full Text] [Related]
20. High-Grade Glioma Radiation Therapy and Reirradiation Treatment Planning Using Translocator Protein Positron Emission Tomography With Fleischmann DF; Büttner M; Unterrainer M; Corradini S; Zollner B; Hofmaier J; Bodensohn R; Thon N; Belka C; Bartenstein P; Albert NL; Niyazi M Adv Radiat Oncol; 2023; 8(3):101185. PubMed ID: 36896209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]